| Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double‐blind treatment phase of a … JM Kremer, R Blanco, M Brzosko, R Burgos‐Vargas, AM Halland, ... Arthritis & Rheumatism 63 (3), 609-621, 2011 | 540 | 2011 |
| Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study W Park, DH Yoo, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, ... Annals of the rheumatic diseases 76 (2), 346-354, 2017 | 295 | 2017 |
| Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis A Deodhar, LS Gensler, J Sieper, M Clark, C Calderon, Y Wang, Y Zhou, ... Arthritis & Rheumatology 71 (2), 258-270, 2019 | 291 | 2019 |
| Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyñski, ... Arthritis & rheumatology 69 (2), 362-375, 2017 | 222 | 2017 |
| The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis A Pawlik, L Ostanek, I Brzosko, M Brzosko, M Masiuk, B Machalinski, ... Arthritis Res Ther 5, 1-4, 2003 | 152 | 2003 |
| Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year … RM Fleischmann, AM Halland, M Brzosko, R Burgos-Vargas, C Mela, ... The Journal of rheumatology 40 (2), 113-126, 2013 | 122 | 2013 |
| Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib R Lehmann, M Brzosko, P Kopsa, R Nischik, A Kreiss, H Thurston, ... Current medical research and opinion 21 (4), 517-526, 2005 | 89 | 2005 |
| Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome H Przepiera-Bêdzak, K Fischer, M Brzosko Mediators of inflammation 2015, 2015 | 78 | 2015 |
| Cardiac arrhythmias and conduction disturbances in patients with ankylosing spondylitis J Kaĵmierczak, M Peregud-Pogorzelska, J Biernawska, ... Angiology 58 (6), 751-756, 2007 | 59 | 2007 |
| TNF-α-308 promoter polymorphism in patients with rheumatoid arthritis. A Pawlik, M Florczak, L Ostanek, M Brzosko, I Brzosko, BG Szklarz Scandinavian journal of rheumatology 34 (1), 2005 | 55 | 2005 |
| Is prevalence of PBC underestimated in patients with systemic sclerosis? GL Norman, A Bialek, S Encabo, B Butkiewicz, A Wiechowska-Kozlowska, ... Digestive and Liver Disease 41 (10), 762-764, 2009 | 52 | 2009 |
| Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from … W Park, MJ Lim, P Miranda, M Brzosko, P Wiland, S Gutierrez-Urena, ... Arthritis and Rheumatism 65 (12), 2013 | 49 | 2013 |
| Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries M Péntek, G Poór, P Wiland, M Olejárová, M Brzosko, C Codreanu, ... The European Journal of Health Economics 15, 35-43, 2014 | 48 | 2014 |
| Stanowisko Zespo³u Ekspertów Konsultanta Krajowego ds. Reumatologii w sprawie diagnostyki i terapii reumatoidalnego zapalenia stawów W T³ustochowicz, M Brzosko, A Filipowicz-Sosnowska, P G³uszko, ... Rheumatologia 46 (3), 2008 | 48 | 2008 |
| Serum interleukin-18, fetuin-A, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome H Przepiera-Bêdzak, K Fischer, M Brzosko International journal of molecular sciences 17 (8), 1255, 2016 | 46 | 2016 |
| Factors associated with quality of life in systemic sclerosis: a cross-sectional study M Sierakowska, H Doroszkiewicz, J Sierakowska, M Olesiñska, ... Quality of Life Research 28, 3347-3354, 2019 | 45 | 2019 |
| Biosimilar switching–current state of knowledge P Wiland, B Batko, M Brzosko, E Kucharz, W Samborski, J Ĥwierkot, ... Reumatologia/Rheumatology 56 (4), 234-242, 2018 | 42 | 2018 |
| High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis O Kowal-Bielecka, M Bielecki, S Guiducci, B Trzcinska-Butkiewicz, ... Arthritis Research & Therapy 15, 1-11, 2013 | 41 | 2013 |
| The distribution of human endogenous retrovirus K-113 in health and autoimmune diseases in Poland M Krzysztalowska-Wawrzyniak, M Ostanek, J Clark, A Binczak-Kuleta, ... Rheumatology 50 (7), 1310-1314, 2011 | 41 | 2011 |
| Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial JM Kremer, R Blanco, AM Halland, M Brzosko, R Burgos-Vargas, ... Clin Exp Rheumatol 34 (4), 625-633, 2016 | 39 | 2016 |
Prof. László Gulácsi, DScBudapest, Hungary, Óbuda UniversityVerified email at uni-obuda.hu
